A Dose-Escalation Study of R1507 [RO4858696] in Patients With Advanced Solid Tumours.
Phase of Trial: Phase I
Latest Information Update: 23 May 2013
At a glance
- Drugs Teprotumumab (Primary)
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 15 Jun 2010 Planned end date changed from 1 Jun 2009 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 21 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 19 Mar 2008 Status change from in progress to recruiting, according to clinicaltrials.gov.